The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Axial oscillations of ion rings are detected by their image current induced on the outer electrode which is split into two symmetrical pick-up sensors connected to a differential amplifier. By processing data in a manner similar to that used in Fourier-transform ion cyclotron resonance mass spectrometry (FTICR-MS), the trap can be used as a mass analyzer. Like in FTICR-MS, all the ions are detected simultaneously over some given period of time and resolution can be improved by increasing the strength of the field or by increasing the detection period. The Orbitrap differs from FTICR-MS by the absence of a magnetic field and hence has a significantly slower decrease of resolving power with increasing m/z.
The Mazda MX-5 was developed around the same time in the US, but had tried to imitate the 1960s Lotus Elan. How Naoki Sakai originated the Italian-heritage Nissan Figaro in the early 1990s - the car, made for Japanese women in a limited production, became so popular that it had to be sold by lottery. How the Mazda research centre at Kanagawa-ku, Yokohama was making intelligent cars.
The researchers found correlations between treatment with antipsychotic drugs and lipid metabolism, in both a lipid-class-specific and drug-specific manner, establishing new foundations around the concept that pharmacometabolomics provides powerful tools for enabling detailed mapping of drug effects. Additional studies by the Pharmacometabolomics Research Network enabled mapping in ways not possible before effects of statins, atenolol and aspirin. Totally new insights were gained about effect of these drugs on metabolism and they highlighted pathways implicated in response and side effects.
Sources: en.wikipedia.org
In August and September, the Columbia team enlarged upon the cross section measurements by making a series of exponential "piles". The first piles consisted of a uranium-graphite lattice, consisting of 288 cans, each containing 60 pounds of uranium oxide, surrounded by graphite bricks. Fermi's goal was to determine critical mass necessary to sustain neutron generation. Fermi defined the reproduction factor k for assessing the chain reaction, with a value of 1.0 denoting a sustained chain reaction. In September 1941, Fermi's team was only able to achieve a k value of 0.87. In April 1942, before the project was centralized in Chicago, they had achieved 0.918 by removing moisture from the oxide. In May 1942, Fermi planned a full-scale chain reacting pile, Chicago Pile-1, after one of the exponential piles at Stagg Field reached a k of 0.995. Between 15 September and 15 November, Herbert L. Anderson and Walter Zinn built sixteen exponential piles. Acquisition of purer forms of graphite, without traces of boron and its large cross section, became paramount. Also important was the acquisition of highly purified forms of oxide from Mallinckrodt Chemical Works. Finally, acquiring pure uranium metal from the Ames process, meant the replacement of oxide pseudospheres with Frank Spedding's "eggs". Starting on 16 November 1942, Fermi had Anderson and Zinn working in two twelve-hours shifts, constructing a pile that eventually reached 57 layers by 1 Dec.
==== Combination drugs ==== Carbidopa/entacapone/levodopa (LECIGel; LECIGon; Lecigon; Trigel) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), entacapone (catechol O-methyltransferase (COMT) inhibitor), and levodopa (dopamine precursor) [345] Levodopa/carbidopa/entacapone (ELC-200; Stalevo; Stavelo) – combination of levodopa (dopamine precursor), carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), and entacapone (catechol O-methyltransferase (COMT) inhibitor) [346]
== Stimulants == A stimulant is defined as an agent (as a drug) that temporarily increases the activity central nervous system and the body. For athletes, stimulants are used for two major reasons: to heighten energy levels and to boast endurance. Examples of stimulants are: amphetamine (Adderall), caffeine (guarana), cocaine, ephedrine, fenfluramine (Fen), methamphetamine, methylphenidate (Ritalin), phentermine (Phen), synephrine (bitter orange). Stimulants phenylephrine and pseudoephedrine aren't banned. The most common abused stimulant by athletes is amphetamine.
atlas evolved from the fusion of a protein-coding gene that arose at the base of Drosophila genus and a conserved non-coding RNA. Comparative analysis of the transcriptomes of testis and accessory glands, a somatic tissue of males that is important for fertility, of D. melanogaster suggests that de novo genes make greater contribution to the transcriptomic complexity of testis as compared to accessory glands. Single-cell RNA-seq of D. melanogaster testis revealed that the expression pattern of de novo genes was biased toward early spermatogenesis. In humans, a study that identified 60 human-specific de novo genes found that their average expression, as measured by RNA-seq, was highest in the testes. Another study looking at mammalian-specific genes more generally also found enriched expression in the testes. Transcription in mammalian testes is thought to be particularly promiscuous, due in part to elevated expression of the transcription machinery and an open chromatin environment. Along with the immune-privileged nature of the testes, this promiscuous transcription is thought to create the ideal conditions for the expression of non-genic sequences required for de novo gene birth. Testes-specific expression seems to be a general feature of all novel genes, as an analysis of Drosophila and vertebrate species found that young genes showed testes-biased expression regardless of their mechanism of origination.
Sources: en.wikipedia.org
Childhood problems related to sickle cells disease were not reported until the 1930s, even though this could not have been uncommon in African-American populations. Memphis physician Lemuel Diggs, a prolific researcher into sickle cell disease, first introduced the distinction between sickle cell disease and trait in 1933. Until 1949, the genetic characteristics had not been elucidated by James V. Neel and E.A. Beet. 1949 was the year when Linus Pauling described the unusual chemical behaviour of haemoglobin S, and attributed this to an abnormality in the molecule itself. The molecular change in HbS was described in 1956 by Vernon Ingram. The late 1940s and early 1950s saw further understanding in the link between malaria and sickle cell disease. In 1954, the introduction of haemoglobin electrophoresis allowed the discovery of particular subtypes, such as HbSC disease. Large-scale natural history studies and further intervention studies were introduced in the 1970s and 1980s, leading to widespread use of prophylaxis against pneumococcal infections among other interventions. Bill Cosby's Emmy-winning 1972 TV movie, To All My Friends on Shore, depicted the story of the parents of a child with sickle cell disease. The 1990s had the development of hydroxycarbamide, and reports of cure through bone marrow transplantation appeared in 2007. Some texts refer to it as drepanocytosis.
William Henry Vanderbilt* (1841), eldest son of Cornelius Vanderbilt; president of the New York Central Railroad, Lake Shore and Michigan Southern Railway, Canada Southern Railway, and Michigan Central Railroad Robert Morrison Olyphant (1842), heir to trading company Olyphant & Co. and president of the Delaware and Hudson Railway Charles Carow* (1844), businessman son of shipping magnate Isaac Carow, father of first lady Edith Carow Roosevelt Frederic W. Rhinelander (1847), 3rd president of the Metropolitan Museum of Art William Backhouse Astor Jr. (1849), son of William Backhouse Astor Sr. and husband of Caroline Webster Schermerhorn Astor, co-founder of The Four Hundred list of socialites and Florida Yacht Club Robert L. Cutting Jr. (1856), banker and clubman, son of Robert L. Cutting '30 George Lovett Kingsland (1856), merchant and railroad executive, son of New York City mayor Ambrose Kingsland Goold H. Redmond (1857), banker and sportsman Charles Henry Marshall (1858), businessman, former commissioner of Docks and Ferries of the City of New York, grandfather of publisher Marshall Field IV John Crosby Brown (1859), heir to investment bank Brown Bros. & Co., which later became Brown Brothers Harriman & Co., the oldest private bank in the U.S. Emory McClintock (1859), actuary; president of the American Mathematical Society and the Actuarial Society of America Robert Goelet (1860), real estate developer Rutherfurd Stuyvesant (1863), socialite, heir to the Stuyvesant family fortune J.
The Academy of Clinical Laboratory Physicians and Scientists is a learned society for scientists in the fields of clinical pathology and laboratory medicine. It was founded on November 12, 1966, in Bethesda, Maryland by a group of fifty-one individuals, led by David Seligson, Jon Straumfjord, George Z. Williams, Ernest Cotlove, and Ellis Benson. The society's founding mission was to represent scientists in the fields of clinical pathology and laboratory medicine in both the United States and Canada. As of 2015, it had 295 active members, as well as an additional 127 associate members, 195 emeritus members, and 5 honorary members. Along with the American Society for Clinical Pathology, it co-sponsors the American Journal of Clinical Pathology.
==== Restless legs syndrome ==== Though not typically a first line of treatment, opioids such as oxycodone and methadone are sometimes used in the treatment of severe and refractory restless legs syndrome.
=== Ancient era (pre-17th century) === An understanding of the inner workings of human tissues may date back further than most would expect. As early as the Neolithic period, sutures were being used to close wounds and aid in healing. Later on, societies such as ancient Egypt developed better materials for sewing up wounds such as linen sutures. Around 2500 BC in ancient India, skin grafts were developed by cutting skin from the buttock and suturing it to wound sites in the ear, nose, or lips. Ancient Egyptians often would graft skin from corpses onto living humans and even attempted to use honey as a type of antibiotic and grease as a protective barrier to prevent infection. In the 1st and 2nd centuries AD, Gallo-Romans developed wrought iron implants and dental implants could be found in ancient Mayans.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.